WO2004108763A3 - Mutants of the factor vii epidermal growth factor domain - Google Patents
Mutants of the factor vii epidermal growth factor domain Download PDFInfo
- Publication number
- WO2004108763A3 WO2004108763A3 PCT/CA2004/000826 CA2004000826W WO2004108763A3 WO 2004108763 A3 WO2004108763 A3 WO 2004108763A3 CA 2004000826 W CA2004000826 W CA 2004000826W WO 2004108763 A3 WO2004108763 A3 WO 2004108763A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mutants
- domain
- epidermal growth
- factor
- growth factor
- Prior art date
Links
- 102000009024 Epidermal Growth Factor Human genes 0.000 title 1
- 101800003838 Epidermal growth factor Proteins 0.000 title 1
- 229940116977 epidermal growth factor Drugs 0.000 title 1
- 229940012413 factor vii Drugs 0.000 title 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title 1
- 230000035772 mutation Effects 0.000 abstract 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 1
- 238000002965 ELISA Methods 0.000 abstract 1
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 abstract 1
- 230000003024 amidolytic effect Effects 0.000 abstract 1
- 239000003114 blood coagulation factor Substances 0.000 abstract 1
- 229940019700 blood coagulation factors Drugs 0.000 abstract 1
- 230000035602 clotting Effects 0.000 abstract 1
- 230000002860 competitive effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000012163 sequencing technique Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002528239A CA2528239A1 (en) | 2003-06-05 | 2004-06-03 | Mutants of the factor vii epidermal growth factor domain |
EP04735858A EP1636358A2 (en) | 2003-06-05 | 2004-06-03 | Mutants of the factor vii epidermal growth factor domain |
US11/294,670 US20060234935A1 (en) | 2003-06-05 | 2005-12-05 | Mutants of the factor VII epidermal growth factor domain |
US11/636,030 US20070207960A1 (en) | 2003-06-05 | 2006-12-08 | Mutants of the factor VII epidermal growth factor domain |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47590503P | 2003-06-05 | 2003-06-05 | |
US60/475,905 | 2003-06-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/294,670 Continuation US20060234935A1 (en) | 2003-06-05 | 2005-12-05 | Mutants of the factor VII epidermal growth factor domain |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004108763A2 WO2004108763A2 (en) | 2004-12-16 |
WO2004108763A3 true WO2004108763A3 (en) | 2005-02-17 |
Family
ID=33511728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2004/000826 WO2004108763A2 (en) | 2003-06-05 | 2004-06-03 | Mutants of the factor vii epidermal growth factor domain |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060234935A1 (en) |
EP (1) | EP1636358A2 (en) |
CA (1) | CA2528239A1 (en) |
WO (1) | WO2004108763A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9476037B2 (en) | 2008-04-11 | 2016-10-25 | Catalyst Biosciences, Inc. | Factor VII polypeptides that are modified and uses thereof |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0514396A2 (en) | 2004-08-17 | 2009-05-12 | Csl Behring Gmbh | modified vitamin K dependent polypeptides |
EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
ES2397851T3 (en) | 2005-07-13 | 2013-03-11 | Novo Nordisk Health Care Ag | Host cell protein inactivation cells for the production of therapeutic proteins |
ES2515915T3 (en) | 2005-09-01 | 2014-10-30 | Novo Nordisk Health Care Ag | Purification of Factor VII polypeptides by hydrophobic interaction chromatography |
WO2007031559A2 (en) | 2005-09-14 | 2007-03-22 | Novo Nordisk Health Care Ag | Human coagulation factor vii polypeptides |
JP5570809B2 (en) | 2006-09-01 | 2014-08-13 | ノボ ノルディスク ヘルス ケア アーゲー | Modified protein |
NZ579985A (en) | 2007-04-13 | 2012-02-24 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof |
JP5909180B2 (en) * | 2009-06-25 | 2016-04-26 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Chimeric factor VII molecule |
CN104211799B (en) * | 2013-05-29 | 2017-12-26 | 成都渊源生物科技有限公司 | Human Epidermal growth factor domain protein and its application |
CN104211802B (en) * | 2013-05-29 | 2018-07-27 | 成都渊源生物科技有限公司 | Human blood coagulation light chain protein and its application |
EP3833381B1 (en) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration |
CN116143929B (en) * | 2023-02-03 | 2023-08-01 | 北京基科晟斯医药科技有限公司 | Antibody against recombinant human coagulation factor VIIa-Fc fusion protein and application thereof |
-
2004
- 2004-06-03 CA CA002528239A patent/CA2528239A1/en not_active Abandoned
- 2004-06-03 WO PCT/CA2004/000826 patent/WO2004108763A2/en active Search and Examination
- 2004-06-03 EP EP04735858A patent/EP1636358A2/en not_active Withdrawn
-
2005
- 2005-12-05 US US11/294,670 patent/US20060234935A1/en not_active Abandoned
Non-Patent Citations (7)
Title |
---|
BROTHERS ALEX B ET AL: "Complete nucleotide sequence of the cDNA encoding rabbit coagulation factor VII", THROMBOSIS RESEARCH, vol. 69, no. 2, 1993, pages 231 - 238, XP009041224, ISSN: 0049-3848 * |
CLARKE B.: "Interspecies exchange mutagenesis of the first growth factor-like domain of human factor VII", J. THROMBOSIS AND HAEMOSTASIS, vol. 1, 2003, SUPPLEMENT 1 JULY, pages ABSTRACT NUMBER P0559, XP001204193 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 1998 (1998-06-01), KAVLIE ANITA ET AL: "Characterization of a factor VII molecule carrying a mutation in the second epidermal growth factor-like domain", XP002309720, Database accession no. PREV199800347106 * |
KAZAMA Y ET AL: "Evidence that an Arg-79 fwdarw Gln substitution in human factor VII is not associated with a reduction in coagulant activity", BLOOD COAGULATION AND FIBRINOLYSIS, vol. 3, no. 6, 1992, pages 697 - 702, XP009041242, ISSN: 0957-5235 * |
PERSSON E ET AL: "Ca2+ in the first epidermal growth factor-like domain of activated factor VII", BLOOD COAGULATION AND FIBRINOLYSIS, vol. 9, no. SUPPL. 1, March 1998 (1998-03-01), & 4TH SYMPOSIUM ON NEW ASPECTS OF HAEMOPHILIA TREATMENT; COPENHAGEN, DENMARK; SEPTEMBER 19-20, 1997, pages S79 - S81, XP009041243, ISSN: 0957-5235 * |
SRIDHARA SAMPATH ET AL: "Activation of a recombinant human factor VII structural analogue alters its affinity of binding to tissue factor", AMERICAN JOURNAL OF HEMATOLOGY, vol. 53, no. 2, 1996, pages 66 - 71, XP009041225, ISSN: 0361-8609 * |
THROMBOSIS AND HAEMOSTASIS, vol. 79, no. 6, June 1998 (1998-06-01), pages 1136 - 1143, ISSN: 0340-6245 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9476037B2 (en) | 2008-04-11 | 2016-10-25 | Catalyst Biosciences, Inc. | Factor VII polypeptides that are modified and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1636358A2 (en) | 2006-03-22 |
CA2528239A1 (en) | 2004-12-16 |
US20060234935A1 (en) | 2006-10-19 |
WO2004108763A2 (en) | 2004-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004108763A3 (en) | Mutants of the factor vii epidermal growth factor domain | |
WO2005063820A3 (en) | Il-7 fusion proteins | |
ATE493148T1 (en) | ANTIBODIES FOR INHIBITING BLOOD CLOTTING AND METHOD OF USE THEREOF | |
WO2008028686A3 (en) | Use of human cells of myeloid leukaemia origin for expression of antibodies | |
WO2001092308A3 (en) | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof | |
JO2828B1 (en) | Anti-Hepcidin Antibodies and Uses Thereof | |
WO2007092640A3 (en) | Antibodies that bind par-2 | |
ATE410178T1 (en) | OLIGOPEPTIDES TO REDUCE INCREASED BLOOD UREA CONCENTRATION | |
SG161247A1 (en) | Variant forms of urate oxidase and use thereof | |
WO2006114105A3 (en) | Use of modified factor vii for treating bleeding | |
PL1969127T5 (en) | Method of producing biologically active vitamin k dependent proteins by recombinant methods | |
WO2008008482A3 (en) | Altered br3-binding polypeptides | |
WO2005056585A3 (en) | Sars coronavirus s proteins and uses thereof | |
IL168435A (en) | Composition comprising recombinant precursor human n-acetylgalactosamine-4-sulfatase, uses thereof and methods for producing and purifying said enzyme | |
WO2007060213A3 (en) | Erythropoietin polypeptides and uses thereof | |
Gundberg et al. | Vitamin K dependent proteins of bone and cartilage | |
WO2003097810A3 (en) | Nitrilases, nucleic acids encoding them and methods for making and using them | |
TW200734638A (en) | Method for the diagnosis of thromboembolic and coronary heart diseases | |
WO2004094476A3 (en) | Compositions and methods relating to stop-1 | |
WO2004081229A3 (en) | Use of bv8 and/or eg-vegf to promote hematopoiesis | |
WO2005018552A3 (en) | Heparin binding proteins: sensors for heparin detection | |
Kim et al. | Existence of stable fibrin-clotting inhibitor in salt-fermented anchovy sauce | |
WO2007143578A3 (en) | Perforin-2 proteins | |
WO2003050134A3 (en) | Crystalline neutrokine-alpha protein, method of preparation thereof, and method of use thereof | |
ATE540967T1 (en) | METHOD FOR PURIFYING PROTEINS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2528239 Country of ref document: CA Ref document number: 11294670 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004735858 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004735858 Country of ref document: EP |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 11294670 Country of ref document: US |